Royalty Pharma Reveals $500 Million R&D Co-Funding Partnership with Johnson & Johnson for 2026-2027
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2026
0mins
Should l Buy JNJ?
Source: moomoo
Funding Announcement: Royalty Pharma has announced a $500 million R&D co-funding agreement with Johnson & Johnson for the years 2026-2027.
Collaboration Details: The agreement aims to support the development of innovative therapies and enhance research capabilities between the two companies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 238.460
Low
190.00
Averages
218.50
High
240.00
Current: 238.460
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson Expected to Report 3.2% Decline in Q1 Earnings
- Earnings Decline Expected: Johnson & Johnson is anticipated to report a 3.2% decline in Q1 earnings on April 14, with a consensus EPS estimate of $2.68, despite a projected revenue increase of 7.8% to $23.61 billion, indicating market concerns over profitability.
- Patent Expiration Impact: The loss of exclusivity for J&J's blockbuster drug Stelara has led to a 41.5% year-over-year sales decline, with the drug contributing 6.5% to total sales in 2025, putting pressure on overall revenue.
- Future Growth Potential: Analysts highlight promising prospects for new drugs like Icotyde and Tremfya in immunology, with Tremfya growing 40% in 2025, which is expected to drive future sales growth despite current challenges.
- Strong Performance Record: Over the past two years, J&J has beaten EPS estimates 88% of the time and revenue estimates 100% of the time, bolstering investor confidence for another solid quarter, with the stock up over 15% year-to-date.
See More
Oil Prices Surge Amid U.S. Tensions; Bank Earnings Reports Loom
- Oil Price Surge: Oil prices jumped 7% today, surpassing $100, following President Trump's announcement of a blockade on the Strait of Hormuz due to failed peace talks with Iran, which could lead to instability in global energy markets.
- Goldman Sachs Earnings Beat: Goldman Sachs reported better-than-expected earnings for Q1, driven by record equity trading results, although disappointing fixed-income trading led to a more than 2% drop in its stock price, highlighting mixed performance in its trading divisions.
- AI Security Risk Discussions: The release of Anthropic's new AI model has raised cybersecurity concerns, prompting Federal Reserve Chair and Treasury Secretary to meet with major bank CEOs to discuss potential risks, indicating heightened government scrutiny over AI technology safety.
- Trump vs. Pope Controversy: Trump criticized Pope Leo XIV on social media for being weak on the Iran war, while the Pope responded by emphasizing his commitment to promoting peace and dialogue, reflecting the ongoing tension between political and religious spheres that may influence public opinion.
See More
Trump Announces Maritime Blockade Against Iran Amid Rising Oil Prices
- Oil Price Surge: Following Trump's announcement of a maritime blockade in the Strait of Hormuz, crude oil prices surged by 7% to surpass $100, indicating potential market volatility and broader economic implications as tensions escalate in the region.
- Bank Earnings Season Begins: Goldman Sachs reported better-than-expected earnings for Q1, driven by record equity trading, yet shares fell over 2% due to disappointing fixed-income results, reflecting investor concerns about future performance amidst a competitive landscape.
- AI Security Risks: The release of Anthropic's new AI model has raised cybersecurity concerns, prompting a meeting between the Federal Reserve Chair and major bank CEOs to discuss potential risks, highlighting the government's increasing scrutiny of AI technologies and their implications for financial institutions.
- Ineos Automotive Startup: Ineos is set to announce record orders for its flagship vehicle, with the CEO aiming for breakeven this year while targeting a 30%-35% annual sales increase in the U.S. market, demonstrating its ambition to disrupt the SUV sector amidst fierce competition.
See More
Bristol Myers Squibb: A New Value Investment Choice
- Valuation Appeal: Bristol Myers Squibb's forward P/E ratio of approximately 9.5 makes it an attractive value stock compared to competitors like Johnson & Johnson and Merck, which have ratios of 21 and 24, potentially drawing interest from value-focused investors.
- Stable Dividend Yield: With a dividend yield of 4.2% and a history of 94 consecutive years of dividend payments, including 17 years of increases, the company demonstrates strong cash flow and commitment to shareholders, bolstering investor confidence.
- Revenue Growth Potential: While revenue for 2024 and 2025 is projected at $48.3 billion and $48.2 billion respectively, with a decline expected in 2026 to between $46 billion and $47.5 billion, the growth portfolio's revenue increased from $22.6 billion to $26.4 billion, indicating strong potential in new drug development.
- Acquisition Strategy: The planned $1.5 billion acquisition of Orbital Therapeutics, despite the existing $47 billion debt, could enhance Bristol's pipeline and help mitigate revenue losses from upcoming patent cliffs, showcasing a strategic vision for long-term growth.
See More
Investment Analysis of Bristol Myers Squibb
- Stable Revenue Performance: Bristol Myers Squibb reported revenues of $48.3 billion in 2024 and $48.2 billion in 2025, with a projected decline to between $46 billion and $47.5 billion in 2026, yet its revenue stability continues to attract investor interest.
- High Dividend Appeal: The company boasts a dividend yield of 4.2%, significantly higher than its competitors, and has increased its dividend for 17 consecutive years while paying dividends for 94 years, demonstrating strong cash flow and shareholder return capabilities.
- Growth Potential and Acquisition Plans: Bristol plans to acquire Orbital Therapeutics for $1.5 billion, which, despite its $47 billion debt, could enhance its drug pipeline and help mitigate revenue losses from upcoming patent cliffs.
- Market Concerns and Value Investment: While the market is worried about declining revenue from its legacy portfolio, Bristol's growth portfolio saw an increase from $22.6 billion to $26.4 billion in 2025, indicating potential in new drug development that may offer long-term value for investors.
See More
Bristol Myers Squibb: A New Opportunity for Value Investors
- Valuation Appeal: Bristol Myers Squibb's forward P/E ratio stands at approximately 9.5, significantly lower than competitors like Johnson & Johnson at 21 and Merck at 24, indicating its potential as a value stock that may attract investors seeking undervalued opportunities.
- Stable Dividend Yield: The company boasts a dividend yield of 4.2% and has increased its dividend for 17 consecutive years while paying dividends for 94 years, showcasing its financial stability and commitment to shareholders, which could bolster investor confidence.
- Revenue Growth and Challenges: While revenue from its legacy portfolio dropped from $25.7 billion in 2024 to $21.8 billion in 2025, revenue from its growth portfolio surged from $22.6 billion to $26.4 billion, indicating potential in new drug development that may alleviate future revenue pressures.
- Acquisition Strategy: Bristol's $1.5 billion acquisition of Orbital Therapeutics, despite its $47 billion debt, could enhance its drug pipeline, particularly in RNA therapeutics, with the market projected to reach $205 billion by 2035, reflecting its long-term growth potential.
See More
Johnson & Johnson Expected to Report 3.2% Decline in Q1 Earnings
- Earnings Decline Expected: Johnson & Johnson is anticipated to report a 3.2% decline in Q1 earnings on April 14, with a consensus EPS estimate of $2.68, despite a projected revenue increase of 7.8% to $23.61 billion, indicating market concerns over profitability.
- Patent Expiration Impact: The loss of exclusivity for J&J's blockbuster drug Stelara has led to a 41.5% year-over-year sales decline, with the drug contributing 6.5% to total sales in 2025, putting pressure on overall revenue.
- Future Growth Potential: Analysts highlight promising prospects for new drugs like Icotyde and Tremfya in immunology, with Tremfya growing 40% in 2025, which is expected to drive future sales growth despite current challenges.
- Strong Performance Record: Over the past two years, J&J has beaten EPS estimates 88% of the time and revenue estimates 100% of the time, bolstering investor confidence for another solid quarter, with the stock up over 15% year-to-date.
See More
Oil Prices Surge Amid U.S. Tensions; Bank Earnings Reports Loom
- Oil Price Surge: Oil prices jumped 7% today, surpassing $100, following President Trump's announcement of a blockade on the Strait of Hormuz due to failed peace talks with Iran, which could lead to instability in global energy markets.
- Goldman Sachs Earnings Beat: Goldman Sachs reported better-than-expected earnings for Q1, driven by record equity trading results, although disappointing fixed-income trading led to a more than 2% drop in its stock price, highlighting mixed performance in its trading divisions.
- AI Security Risk Discussions: The release of Anthropic's new AI model has raised cybersecurity concerns, prompting Federal Reserve Chair and Treasury Secretary to meet with major bank CEOs to discuss potential risks, indicating heightened government scrutiny over AI technology safety.
- Trump vs. Pope Controversy: Trump criticized Pope Leo XIV on social media for being weak on the Iran war, while the Pope responded by emphasizing his commitment to promoting peace and dialogue, reflecting the ongoing tension between political and religious spheres that may influence public opinion.
See More
Trump Announces Maritime Blockade Against Iran Amid Rising Oil Prices
- Oil Price Surge: Following Trump's announcement of a maritime blockade in the Strait of Hormuz, crude oil prices surged by 7% to surpass $100, indicating potential market volatility and broader economic implications as tensions escalate in the region.
- Bank Earnings Season Begins: Goldman Sachs reported better-than-expected earnings for Q1, driven by record equity trading, yet shares fell over 2% due to disappointing fixed-income results, reflecting investor concerns about future performance amidst a competitive landscape.
- AI Security Risks: The release of Anthropic's new AI model has raised cybersecurity concerns, prompting a meeting between the Federal Reserve Chair and major bank CEOs to discuss potential risks, highlighting the government's increasing scrutiny of AI technologies and their implications for financial institutions.
- Ineos Automotive Startup: Ineos is set to announce record orders for its flagship vehicle, with the CEO aiming for breakeven this year while targeting a 30%-35% annual sales increase in the U.S. market, demonstrating its ambition to disrupt the SUV sector amidst fierce competition.
See More
Bristol Myers Squibb: A New Value Investment Choice
- Valuation Appeal: Bristol Myers Squibb's forward P/E ratio of approximately 9.5 makes it an attractive value stock compared to competitors like Johnson & Johnson and Merck, which have ratios of 21 and 24, potentially drawing interest from value-focused investors.
- Stable Dividend Yield: With a dividend yield of 4.2% and a history of 94 consecutive years of dividend payments, including 17 years of increases, the company demonstrates strong cash flow and commitment to shareholders, bolstering investor confidence.
- Revenue Growth Potential: While revenue for 2024 and 2025 is projected at $48.3 billion and $48.2 billion respectively, with a decline expected in 2026 to between $46 billion and $47.5 billion, the growth portfolio's revenue increased from $22.6 billion to $26.4 billion, indicating strong potential in new drug development.
- Acquisition Strategy: The planned $1.5 billion acquisition of Orbital Therapeutics, despite the existing $47 billion debt, could enhance Bristol's pipeline and help mitigate revenue losses from upcoming patent cliffs, showcasing a strategic vision for long-term growth.
See More
Investment Analysis of Bristol Myers Squibb
- Stable Revenue Performance: Bristol Myers Squibb reported revenues of $48.3 billion in 2024 and $48.2 billion in 2025, with a projected decline to between $46 billion and $47.5 billion in 2026, yet its revenue stability continues to attract investor interest.
- High Dividend Appeal: The company boasts a dividend yield of 4.2%, significantly higher than its competitors, and has increased its dividend for 17 consecutive years while paying dividends for 94 years, demonstrating strong cash flow and shareholder return capabilities.
- Growth Potential and Acquisition Plans: Bristol plans to acquire Orbital Therapeutics for $1.5 billion, which, despite its $47 billion debt, could enhance its drug pipeline and help mitigate revenue losses from upcoming patent cliffs.
- Market Concerns and Value Investment: While the market is worried about declining revenue from its legacy portfolio, Bristol's growth portfolio saw an increase from $22.6 billion to $26.4 billion in 2025, indicating potential in new drug development that may offer long-term value for investors.
See More
Bristol Myers Squibb: A New Opportunity for Value Investors
- Valuation Appeal: Bristol Myers Squibb's forward P/E ratio stands at approximately 9.5, significantly lower than competitors like Johnson & Johnson at 21 and Merck at 24, indicating its potential as a value stock that may attract investors seeking undervalued opportunities.
- Stable Dividend Yield: The company boasts a dividend yield of 4.2% and has increased its dividend for 17 consecutive years while paying dividends for 94 years, showcasing its financial stability and commitment to shareholders, which could bolster investor confidence.
- Revenue Growth and Challenges: While revenue from its legacy portfolio dropped from $25.7 billion in 2024 to $21.8 billion in 2025, revenue from its growth portfolio surged from $22.6 billion to $26.4 billion, indicating potential in new drug development that may alleviate future revenue pressures.
- Acquisition Strategy: Bristol's $1.5 billion acquisition of Orbital Therapeutics, despite its $47 billion debt, could enhance its drug pipeline, particularly in RNA therapeutics, with the market projected to reach $205 billion by 2035, reflecting its long-term growth potential.
See More
